Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: A double-blind, placebo-controlled, multicentre trial
Aarsland D et al. – Pts with dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD) may benefit from treatment with the N-methyl D-aspartate (NMDA) receptor antagonist memantine, pending confirmation of preliminary findings by large-scale studies. Treatment with memantine was well tolerated. Methods- Study of safety and efficacy of memantine in pts with PDD or DLB
- Parallel-group, 24-week, randomized controlled study of memantine (20 mg/day) vs placebo at 4 psychiatric and neurologic outpatient clinics in Norway, Sweden, and the UK during 2005-2008
- Subjects fulfilled UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria for PD and developed dementia (PDD) by DSM IV criteria ≥1 yr after onset of motor symptoms or met revised consensus operationalized criteria for DLB
- Physicians masked to pt treatment allocation
- Primary outcome measure: clinical global impression of change (CGIC), ranging from 1-7 points; low score = better outcome
Results- Treatment for 72 pts with PDD or DLB: 34 with memantine and 38 with placebo
- Study completion by 56 (78%)
- All withdrawals due to adverse events; similar proportion of withdrawals for both groups
- At wk 24, memantine pts had better CGIC scores vs placebo pts
- Except improved speed on attentional tasks in memantine pts, no significant differences between groups in secondary outcome measures
[more...]
|
|
|
